Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

MRAM: A Versatile Non-Volatile Memory for Next-Generation Computing.

Nanomaterials (Basel, Switzerland)·2026

Same author

Dynamic evolution of readmission risk factors across short-, medium-, and long-term horizons in type 2 diabetes: a machine learning-based predictive modeling study with SHAP interpretability.

Frontiers in endocrinology·2026

Same author

Counteracting vitamin D receptor signaling deficiency rescues subcutaneous adipose loss in aging.

Protein & cell·2026

Same author

Reference intervals for venous blood gas measurement in a healthy Chinese population.

Clinica chimica acta; international journal of clinical chemistry·2026

Same author

The Lamin Proteins in Nuclear Structure, Functions, and Laminopathies.

Cells·2026

Same author

Exosomal miRNA-714 derived from adipose tissue macrophages regulates adipocyte glucose and lipid metabolism via IGF1R targeting.

Nutrition & metabolism·2026

Search research articles

Related Experiment Video

Updated: Jul 18, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Developing Effective Cancer Vaccines Using Rendered-Inactive Tumor Cells.

Shushu Zhao¹, Shuting Wu¹, Sheng Jiang¹

¹Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.

|August 26, 2023

Summary

Cancer vaccines using inactivated tumor cells show promise. Combining these vaccines with anti-CD25 antibodies enhances tumor suppression and may offer a new strategy for cancer prevention.

Keywords:

anti-CD25 antibody antitumor growth inactivated tumor cells regulatory T cells tumor-cell-based vaccine

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jul 18, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Area of Science:

Immunology
Oncology
Vaccine Development

Background:

Cancer remains a significant global health challenge, necessitating novel therapeutic strategies.
Cancer vaccines aim to harness the immune system to combat malignancies.
Developing effective cancer vaccines using tumor-derived materials is an active area of research.

Purpose of the Study:

To investigate the efficacy of mitomycin C-inactivated tumor cells as a cancer vaccine.
To explore the role of dendritic cell (DC) activation and T cell responses in tumor protection.
To evaluate combination strategies involving inactivated tumor cells and regulatory T cell (Treg) depletion for enhanced cancer prevention.

Main Methods:

Utilized CMS5 fibrosarcoma and E.G7 lymphoma tumor models in mice.
Administered mitomycin C-inactivated tumor cells as a vaccine.
Assessed tumor protection, DC maturation and activation, and CD8+ T cell dependency.
Investigated the impact of combining inactivated tumor cells with anti-CD25 antibodies to deplete Treg cells.

Main Results:

Immunization with inactivated CMS5 cells significantly suppressed CMS5 tumors but not E.G7 tumors.
Mitomycin C-treated CMS5 cells promoted DC maturation, activation, and phagocytosis in vitro.
Tumor protection mediated by inactivated CMS5 cells was dependent on CD8+ T cells.
Combining inactivated CMS5 cells with anti-CD25 antibodies enhanced tumor prevention efficacy, induced rejection of E.G7 tumors, and elicited responses against heterologous tumors.

Conclusions:

Dendritic cell responses to tumor antigens are crucial for vaccine efficacy.
CD8+ T cells play a vital role in the anti-tumor effects of inactivated tumor cell vaccines.
Combining inactivated tumor cell immunization with Treg depletion (using anti-CD25 antibodies) represents a promising strategy for broad-spectrum cancer prevention.